Nafamostat Mesylate is a synthetic serine protease inhibitor that functions as a short-acting anticoagulant, primarily used to manage acute pancreatitis and prevent postreperfusion syndrome during liver… Read more

![Chemical structure of 4-[(Aminocarbonyl)amino]benzoic acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F6306-25-8-4-Aminocarbonylaminobenzoic-acid.png&w=3840&q=75)




Nafamostat Mesylate is a synthetic serine protease inhibitor that functions as a short-acting anticoagulant, primarily used to manage acute pancreatitis and prevent postreperfusion syndrome during liver transplantation. By inhibiting enzymes such as trypsin and chymotrypsin, this compound plays a critical role in addressing inflammatory cascades. This category provides essential pharmaceutical reference standards required for rigorous quality control and analytical testing of the drug. Laboratories rely on these high-quality materials, including identified process-related impurities, potential nitroso derivatives, and stable isotope-labelled compounds, to support impurity profiling and method validation. Using these precise standards enables accurate identification and quantification of impurities in complex matrices, ensuring compliance with regulatory guidelines and the integrity of pharmaceutical manufacturing. By incorporating these related compounds, analytical chemists can maintain the precision needed for consistent development and safety assessments of Nafamostat Mesylate formulations.